Effects of Bifidobacterium Longum Subsp. Infantis i18 on Gut Microbiota Development and Health in Early Life (Bifido i18)
Effects of Bifidobacterium Longum Subsp. Infantis i18 Intervention on Early-Life Gut Microbiota Development and Health Outcomes: A Randomized, Double-Blind, Multicenter, Placebo-Controlled Clinical Study
This study aims to evaluate the effects of Bifidobacterium longum subsp. infantis i18 supplementation on symptoms, gut microbiota development, and overall health outcomes in healthy infants and young children in China.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Jie Yuan
- Phone Number: +86 19821872781
- Email: 19821872781@163.com
Study Locations
-
-
Hebei
-
Zhangjiakou, Hebei, China
- First Hospital Hebei North University
-
Contact:
- Erwei Yuan
- Phone Number: +86 13301878331
- Email: 13301878331@163.com
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
-
For the Probiotic and Placebo Groups:
- Healthy infants and young children aged 0-36 months at enrollment, born at 37-42 weeks of gestation with a birth weight of 2500-4000 g, receiving formula feeding and/or mixed feeding.
- Classified as being at high risk according to the study-defined assessment criteria.
- No clinically diagnosed allergic disease at enrollment.
- Written informed consent provided by the legal guardian.
For the Observational Reference Group:
- Healthy infants aged 0-6 months at enrollment, born at 37-42 weeks of gestation with a birth weight of 2500-4000 g, exclusively breastfed.
- Classified as being at high risk according to the study-defined assessment criteria.
- No clinically diagnosed allergic disease at enrollment.
- Written informed consent provided by the legal guardian.
Exclusion Criteria:
- Maternal history of metabolic or infectious diseases.
- High-risk pregnancy, or maternal history of alcohol, drug, or other substance abuse during pregnancy.
- Antibiotic use within 4 weeks before enrollment.
- Probiotic product use within 4 weeks before enrollment; for infants younger than 1 month, any use since birth.
- Immunosuppressive therapy before enrollment.
- Acute or chronic disease within 4 weeks before enrollment that may significantly affect growth and development.
- Congenital malformations or birth defects.
- Malnutrition requiring hospitalization.
- Known allergy to any component of the study probiotic product.
- Participation in another clinical trial or use of any investigational drug within 3 months before screening; for infants younger than 3 months, any such participation or use since birth.
- Any other condition considered by the investigator to potentially affect participant safety or interpretation of study data.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Placebo Comparator: Placebo Group
|
Matching placebo without the probiotic intervention |
|
Experimental: Probiotic Group
|
Bifidobacterium longum subsp. infantis i18 supplementation. |
|
No Intervention: Observational Reference Group
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Number of participants with newly reported allergic symptoms (atopic dermatitis/eczema etc.) as assessed with the structured allergy symptom questionnaire
Time Frame: From randomisation (Day 0) to the end of follow-up (Day 180; up to 26 weeks), assessed at each scheduled study visit.
|
From randomisation (Day 0) to the end of follow-up (Day 180; up to 26 weeks), assessed at each scheduled study visit.
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Number of participants with newly reported respiratory symptoms (respiratory tract infection etc.) as assessed with the structured respiratory symptom questionnaire
Time Frame: From randomisation (Day 0) to the end of follow-up (Day 180; up to 26 weeks), assessed at each scheduled study visit.
|
From randomisation (Day 0) to the end of follow-up (Day 180; up to 26 weeks), assessed at each scheduled study visit.
|
|
Number of participants with newly reported gastrointestinal symptoms (constipation etc.) as assessed with the structured gastrointestinal symptom questionnaire
Time Frame: From randomisation (Day 0) to the end of follow-up (Day 180; up to 26 weeks), assessed at each scheduled study visit.
|
From randomisation (Day 0) to the end of follow-up (Day 180; up to 26 weeks), assessed at each scheduled study visit.
|
|
Feeding pattern as assessed with the structured feeding questionnaire
Time Frame: From baseline (Day 0) to the end of follow-up (Day 180; up to 26 weeks), measured at each scheduled study visit.
|
From baseline (Day 0) to the end of follow-up (Day 180; up to 26 weeks), measured at each scheduled study visit.
|
|
Growth and nutritional status: body weight (kg), length/height (cm) and head circumference (cm) measured with a calibrated scale, infantometer/stadiometer and measuring tape, with age- and sex-adjusted Z-scores per WHO Child Growth Standards
Time Frame: From baseline (Day 0) to the end of follow-up (Day 180; up to 26 weeks), measured at each scheduled study visit.
|
From baseline (Day 0) to the end of follow-up (Day 180; up to 26 weeks), measured at each scheduled study visit.
|
|
Gut microbiota composition and diversity: relative abundance (%), alpha diversity and beta diversity in faecal samples assessed by metagenomic sequencing.
Time Frame: From baseline (Day 0) to the end of follow-up (Day 180; up to 26 weeks), faecal samples collected at each scheduled study visit.
|
From baseline (Day 0) to the end of follow-up (Day 180; up to 26 weeks), faecal samples collected at each scheduled study visit.
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Estimated)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- DICT-2026-01-03
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.